Los Angeles Capital Management LLC Sells 8,761 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Los Angeles Capital Management LLC reduced its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 8.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,567 shares of the biotechnology company’s stock after selling 8,761 shares during the period. Los Angeles Capital Management LLC’s holdings in United Therapeutics were worth $32,455,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. LSV Asset Management lifted its holdings in United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after buying an additional 436,851 shares during the period. Swedbank AB bought a new stake in shares of United Therapeutics during the 1st quarter valued at about $97,316,000. Canada Pension Plan Investment Board grew its stake in United Therapeutics by 567.2% during the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock worth $41,533,000 after purchasing an additional 153,700 shares during the period. Assetmark Inc. grew its stake in United Therapeutics by 56.9% during the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after purchasing an additional 152,249 shares during the period. Finally, Pacer Advisors Inc. lifted its stake in United Therapeutics by 19.6% in the second quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after buying an additional 92,240 shares during the period. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Up 1.8 %

Shares of NASDAQ:UTHR opened at $410.00 on Monday. The firm has a market capitalization of $18.31 billion, a PE ratio of 18.01, a P/E/G ratio of 1.20 and a beta of 0.56. The company has a 50-day moving average price of $359.20 and a two-hundred day moving average price of $323.38. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same period last year, the company earned $5.38 earnings per share. Analysts anticipate that United Therapeutics Co. will post 25.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 15,000 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $401.44, for a total value of $6,021,600.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $1,034,510.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $344.18, for a total value of $1,239,048.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $44,743.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 15,000 shares of United Therapeutics stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $401.44, for a total transaction of $6,021,600.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $1,034,510.88. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 96,422 shares of company stock worth $35,251,428 in the last three months. 11.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on UTHR shares. Argus raised their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Oppenheimer boosted their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. TD Cowen upped their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Finally, HC Wainwright upped their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.